Zimmer Biomet's latest quarter underscores its commitment to expanding technological capabilities through acquisitions like Monogram Technologies and Paragon 28. The company maintains a strong liquidity position despite significant debt, aided by a strategic global restructuring plan approved in 2025 aimed at improving efficiency. Its diversified product portfolio across orthopedic segments, paired with geographic reach and cybersecurity initiatives, fortify its competitive moat amid industry challenges. Key risks include execution of restructuring and managing financial leverage.